Terms: = Prostate cancer AND ER, estrogen receptor AND Prognosis
103 results:
1. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
2. The Transcriptomic Profiles of
Olczak M; Orzechowska MJ; Bednarek AK; Lipiński M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176106
[TBL] [Abstract] [Full Text] [Related]
3. Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive cancers: Breast cancer, Cervical cancer, Endometrial cancer, Ovarian cancer and prostate cancer.
Korbecki J; Bosiacki M; Barczak K; Łagocka R; Brodowska A; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108425
[TBL] [Abstract] [Full Text] [Related]
4. The effect of a phytoestrogen intervention and impact of genetic factors on tumor proliferation markers among Swedish patients with prostate cancer: study protocol for the randomized controlled PRODICA trial.
Ahlin R; Nybacka S; Josefsson A; Stranne J; Steineck G; Hedelin M
Trials; 2022 Dec; 23(1):1041. PubMed ID: 36544211
[TBL] [Abstract] [Full Text] [Related]
5. Environmental microcystin exposure triggers the poor prognosis of prostate cancer: Evidence from case-control, animal, and in vitro studies.
Pan C; Qin H; Yan M; Qiu X; Gong W; Luo W; Guo H; Han X
J Environ Sci (China); 2023 May; 127():69-81. PubMed ID: 36522098
[TBL] [Abstract] [Full Text] [Related]
6. Sex Hormone-regulated
Fang Z; Killick C; Halfpenny C; Frewer N; Frewer KA; Ruge F; Jiang WG; Ye L
Cancer Genomics Proteomics; 2022; 19(6):703-710. PubMed ID: 36316045
[TBL] [Abstract] [Full Text] [Related]
7. Therapeutics targeting the metastatic breast cancer bone microenvironment.
Ihle CL; Wright-Hobart SJ; Owens P
Pharmacol Ther; 2022 Nov; 239():108280. PubMed ID: 36116682
[TBL] [Abstract] [Full Text] [Related]
8. Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target.
Qie S; Sang N
J Exp Clin Cancer Res; 2022 May; 41(1):161. PubMed ID: 35501821
[TBL] [Abstract] [Full Text] [Related]
9. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract] [Full Text] [Related]
10. Androgen receptor as an Emerging Feasible Biomarker for Breast cancer.
You CP; Leung MH; Tsang WC; Khoo US; Tsoi H
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220
[TBL] [Abstract] [Full Text] [Related]
11. Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
Hernandez I; Cohen M
Cancer Lett; 2022 Jan; 524():1-14. PubMed ID: 34637844
[TBL] [Abstract] [Full Text] [Related]
12. Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression.
Hu L; Chen X; Narwade N; Lim MGL; Chen Z; Tennakoon C; Guan P; Chan UI; Zhao Z; Deng M; Xu X; Sung WK; Cheung E
Oncogene; 2021 Nov; 40(47):6479-6493. PubMed ID: 34611310
[TBL] [Abstract] [Full Text] [Related]
13. estrogen receptor ß in cancer: To ß(e) or not to ß(e)?
Hwang NM; Stabile LP
Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34370841
[TBL] [Abstract] [Full Text] [Related]
14. Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review.
Jahan N; Jones C; Rahman RL
Mol Cell Endocrinol; 2021 Jul; 531():111324. PubMed ID: 34000352
[TBL] [Abstract] [Full Text] [Related]
15. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.
Zhou L; Song Z; Hu J; Liu L; Hou Y; Zhang X; Yang X; Chen K
Theranostics; 2021; 11(2):841-860. PubMed ID: 33391508
[TBL] [Abstract] [Full Text] [Related]
16. Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases.
Shen Q; Zhou Z; Liu Z; Hu S; Lin Z; Li S; Li S; Song H; Chen Y; Meng Y; Wang Y; Fan Y; Li X; Xiao Y; He Q; Jin J; Zhang Q; Yu W
Urol Int; 2021; 105(3-4):206-214. PubMed ID: 33221793
[TBL] [Abstract] [Full Text] [Related]
17. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
18. Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and prostate cancer.
Ge H; Yan Y; Yan M; Guo L; Mao K
Med Sci Monit; 2020 Jun; 26():e923208. PubMed ID: 32562536
[TBL] [Abstract] [Full Text] [Related]
19. Allergy, asthma, and the risk of breast and prostate cancer: a Mendelian randomization study.
Jiang X; Dimou NL; Zhu Z; Bonilla C; Lewis SJ; Lindström S; Kraft P; Tsilidis KK; Martin RM;
Cancer Causes Control; 2020 Mar; 31(3):273-282. PubMed ID: 32006205
[TBL] [Abstract] [Full Text] [Related]
20. Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer.
Lee YG; Nam Y; Shin KJ; Yoon S; Park WS; Joung JY; Seo JK; Jang J; Lee S; Nam D; Caino MC; Suh PG; Chan Chae Y
Cancer Lett; 2020 Feb; 471():72-87. PubMed ID: 31838085
[TBL] [Abstract] [Full Text] [Related]
[Next]
